Price
No data yet.
Social Signal Score
Revenue
$15.09M-38.68%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Roberto Cingolani
- Sector
- Financial Services
- Industry
- Asset Management - Income
- Employees
- 53,778
- Beta
- 0.62
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 0.93
Financials
Revenue
$15.09M-38.7%Net Income
$5.22M-83.0%EBITDA
$8.63M-72.7%Free Cash Flow
$7.60M-75.2%EPS (diluted)
$0.08-83.6%Shares Outstanding (diluted)
62.29M+2.8%Operating Expenses
$0.00Cash & Debt
$86.6KReturn of Capital
$10.40MDividend per Share
$0.03Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $-5.18M | $-13.10M | $-0.21 |
| 2024 | $73.46M | $73.51M | $1.18 |
| 2023 | $15.78M | $5.12M | $0.03 |
| 2022 | $20.76M | $-111.26M | $-1.79 |
| 2021 | $47.29M | $47.30M | $0.76 |
| 2020 | $23.28M | $7.95M | $0.11 |
| 2019 | $53.22M | $53.26M | $0.82 |
| 2018 | $5.37M | $5.23M | $0.08 |
| 2017 | $3.74M | $3.60M | $0.03 |
| 2016 | $44.42M | $39.10M | $0.72 |
| 2015 | $40.05M | $31.64M | $0.51 |
| 2014 | $39.82M | $79.16M | $1.28 |
| 2013 | $39.77M | $-39.88M | $-0.64 |
| 2012 | $42.09M | $91.67M | $1.49 |
Valuation
LEOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-23.08%Social Signal Score
Mentions (4)
- Newsbusinesswire.com·5d ago·Neutral
LEO Pharma presents new tralokinumab data at EADV 2026 highlighting real-world outcomes and quality of life in adults and adolescents with atopic dermatitis (AD) involving high-burden areas BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma presents new tralokinumab data at EADV 2026.
View source ↗ - Newsbusinesswire.com·18d ago·Neutral
LEO Pharma Announces FDA Acceptance of Dersimelagon NDA with Priority Review and Closes Acquisition from Tanabe Pharma BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma announces FDA acceptance of dersimelagon NDA with Priority Review and closes acquisition from Tanabe Pharma.
View source ↗ - Newsreuters.com·49d ago·Negative
LEO Pharma buys worldwide dersimelagon rights for up to $435 million Danish drugmaker LEO Pharma said on Tuesday it had agreed to acquire worldwide rights to drug candidate dersimelagon from Tanabe Pharma for up to $435 million in up-front and near-term milestone payments.
View source ↗ - Newszacks.com·55d ago·Positive
KVH Industries Stock Slips Post Q2 Earnings, Revenues Up on LEO Growth KVHI's LEO transition in second-quarter 2026 gains momentum as Starlink and OneWeb growth boost airtime revenues, while rising costs pressure profitability.
View source ↗
Insider trading
Open-market buys and sells by LEO officers and directors.
- Bought
- $538k
- Sold
- $89k
9 trades
16 trades
- Bank Of America Corp /de/bought
- Bank Of America Corp /de/sold
- Bank Of America Corp /de/sold
- Bank Of America Corp /de/sold
- Bank Of America Corp /de/sold
- Bank Of America Corp /de/sold
- Bank Of America Corp /de/sold
- Bank Of America Corp /de/sold
75 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in LEO.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.